Safety record
NAD+ safety and side effects
A tolerable ingredient and a well-made preparation answer different questions. Both matter, and neither settles every long-term concern.
Side effects in oral precursor trials
In the 8-week NR trial in healthy overweight adults, adverse events did not differ significantly from placebo at the amounts studied. NR did not cause flushing or raise LDL cholesterol. The 60-day NMN trial in healthy middle-aged adults reported no safety issues at the tested amounts.
Those results deserve room in a safety discussion. I take short-term tolerability seriously without asking it to answer questions that require much longer observation. The study populations and durations are set out in the NAD+ dosage records.
The 10-week NMN study in prediabetic postmenopausal women adds another specific human setting. Together these trials describe the weeks observed; they leave lifetime exposure unresolved.
Tolerability was observed within a particular trial period, population and set of study amounts.
NAD injection and NAD IV therapy
An NAD injection introduces NAD+ without the digestive route used by an oral precursor. NAD IV therapy delivers it into a vein. Controlled evidence for these routes is limited, and NAD+ has no FDA approval as a drug.
Reports of IV infusion describe nausea, flushing, chest discomfort and abdominal discomfort when the infusion runs too fast. These effects were reported as transient and eased when the infusion slowed or stopped. The reports do not establish a universal duration for side effects.
I object to importing the oral safety record wholesale into this discussion. The ingredient, exposure and preparation all need attention. The human precursor review concerns a different evidence base; it cannot certify an injectable preparation.
A separate experiment on human skin fibroblasts in culture found that extracellular NAD broke down at the cell surface before uptake of its products. These were cells in a dish. That paper measured neither IV blood clearance nor treatment benefit in a person.
Compounded preparations and endotoxin
FDA recalled a compounded NAD+ injection for elevated bacterial endotoxin. The recall's classification was Class I, FDA's most serious category. Endotoxin is harmful bacterial material; a clear solution or a tidy room cannot establish its absence.
Preparation quality adds a practical risk to the biological questions. Products prepared in different settings can vary in purity and sterility, while supplement content can also differ from its label and third-party testing is not guaranteed.
The recall persuades me that manufacturing quality merits a full paragraph of its own. A discussion confined to the molecule's natural presence in the body would miss this documented failure.
Daily use and cancer questions
Daily oral precursor trials reported tolerability over their particular study periods. The 2025 review found that clinical efficacy remains limited and tissue data sparse, so the available record leaves important long-term questions open.
The possibility of supporting an existing cancer comes from the context-dependent biology of NAD+ and cell growth. It is a theoretical concern rather than a human trial finding that pills caused cancer. The cell survival page examines why mouse liver findings make a broad reassurance equally unsatisfying.
In a cancer context, that uncertainty strengthens my preference for careful clinical assessment. It supplies no estimate of an individual's risk.
Regulatory status
NAD+ has no FDA approval as a drug, and compounded injectable NAD+ is not FDA-approved.
FDA has taken the position that NMN is excluded from the dietary-supplement definition because drug investigation came first. That position is disputed and creates marketplace uncertainty; it does not by itself make NMN illegal.
NAD+, NMN, NR and nicotinamide are not prohibited by WADA. Permission under sports rules addresses a different question from medical safety or clinical benefit.